Citadel Securities Maintains an 'Edge Negative' on Celgene (CELG); Behind the Smoke and Mirrors: Revlimid Ex-U.S. Growth Updated Guidance Suggests Slowdown Ahead

July 28, 2011 4:34 PM EDT Send to a Friend
Get Alerts CELG Hot Sheet
Price: $124.91 +1.16%

Rating Summary:
    19 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 35 | New: 23
Trade CELG Now!
Citadel Securities maintains an 'Edge Negative' on Celgene (NASDAQ: CELG) price target of $47.

Citadel analyst says, "We are maintaining our Edge Negative Rating and 12-month $47 price target based on our expectation for a near-term deceleration in Revlimid revenue growth. We are updating our model to reflect increased ex-U.S. Abraxane revenues, offset by slowing ex-U.S. Revlimid revenue growth and higher operating expenses and a higher tax rate. Our FY revenue estimate increases to $4,607.9MM from $4,540.3MM, and our adjusted EPS estimate increases to $3.47 from $3.36."

For more ratings news on Celgene click here and for the rating history of Celgene click here.

Shares of Celgene closed at $59.48 yesterday, with a 52 week range of $48.92-$63.46.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments

Add Your Comment